Trevor Nydam
Concepts (343)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 46 | 2026 | 822 | 8.690 |
Why?
| | Kidney Transplantation | 18 | 2026 | 704 | 2.970 |
Why?
| | Tissue and Organ Procurement | 12 | 2026 | 346 | 2.870 |
Why?
| | Obesity, Morbid | 7 | 2025 | 275 | 2.510 |
Why?
| | Gastric Bypass | 4 | 2023 | 124 | 2.350 |
Why?
| | Thrombelastography | 14 | 2025 | 178 | 2.260 |
Why?
| | Tissue Donors | 13 | 2026 | 424 | 2.000 |
Why?
| | Organ Preservation | 7 | 2026 | 130 | 1.990 |
Why?
| | Living Donors | 8 | 2022 | 280 | 1.860 |
Why?
| | Tissue Plasminogen Activator | 7 | 2023 | 244 | 1.800 |
Why?
| | Blood Coagulation Disorders | 5 | 2025 | 189 | 1.670 |
Why?
| | Death | 4 | 2023 | 130 | 1.500 |
Why?
| | Perfusion | 5 | 2026 | 250 | 1.490 |
Why?
| | Fibrinolysis | 6 | 2025 | 162 | 1.340 |
Why?
| | Donor Selection | 6 | 2025 | 79 | 1.180 |
Why?
| | Graft Survival | 14 | 2026 | 526 | 1.170 |
Why?
| | Bariatric Surgery | 3 | 2025 | 236 | 1.160 |
Why?
| | Kidney Failure, Chronic | 6 | 2026 | 597 | 1.060 |
Why?
| | Gastrectomy | 7 | 2025 | 157 | 1.030 |
Why?
| | Cold Ischemia | 5 | 2026 | 40 | 0.970 |
Why?
| | Carcinoma, Hepatocellular | 8 | 2023 | 370 | 0.970 |
Why?
| | End Stage Liver Disease | 7 | 2025 | 94 | 0.910 |
Why?
| | Delayed Graft Function | 5 | 2026 | 46 | 0.890 |
Why?
| | Blood Transfusion | 6 | 2025 | 405 | 0.880 |
Why?
| | Kidney | 8 | 2022 | 1495 | 0.790 |
Why?
| | Liver Neoplasms | 8 | 2023 | 780 | 0.790 |
Why?
| | Hepatitis C | 3 | 2022 | 254 | 0.750 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 35 | 0.750 |
Why?
| | Resuscitation | 2 | 2024 | 302 | 0.700 |
Why?
| | Organ Transplantation | 3 | 2025 | 247 | 0.680 |
Why?
| | Reperfusion | 1 | 2020 | 54 | 0.640 |
Why?
| | Brain Death | 5 | 2026 | 60 | 0.640 |
Why?
| | Postoperative Complications | 6 | 2026 | 2916 | 0.640 |
Why?
| | Humans | 85 | 2026 | 144261 | 0.630 |
Why?
| | Robotic Surgical Procedures | 4 | 2026 | 182 | 0.630 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 51 | 0.620 |
Why?
| | Hepatitis C, Chronic | 1 | 2022 | 152 | 0.620 |
Why?
| | Blood Component Transfusion | 1 | 2020 | 103 | 0.600 |
Why?
| | Decision Support Techniques | 7 | 2025 | 454 | 0.580 |
Why?
| | Graft Rejection | 2 | 2020 | 540 | 0.580 |
Why?
| | Apoptosis | 5 | 2021 | 2430 | 0.570 |
Why?
| | Amino Acid Chloromethyl Ketones | 1 | 2018 | 24 | 0.570 |
Why?
| | Organ Preservation Solutions | 1 | 2018 | 47 | 0.560 |
Why?
| | Middle Aged | 39 | 2026 | 35762 | 0.560 |
Why?
| | Heart Failure | 2 | 2023 | 2314 | 0.560 |
Why?
| | Caspase Inhibitors | 1 | 2018 | 81 | 0.550 |
Why?
| | Blood Coagulation | 6 | 2023 | 268 | 0.540 |
Why?
| | Pneumoperitoneum | 1 | 2017 | 12 | 0.540 |
Why?
| | Retrospective Studies | 27 | 2026 | 17009 | 0.540 |
Why?
| | Klebsiella Infections | 1 | 2017 | 26 | 0.530 |
Why?
| | Cholecystitis | 1 | 2017 | 23 | 0.530 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 81 | 0.530 |
Why?
| | Thrombophilia | 1 | 2018 | 88 | 0.530 |
Why?
| | Cholecystectomy | 1 | 2017 | 59 | 0.520 |
Why?
| | Quinolines | 1 | 2018 | 190 | 0.510 |
Why?
| | Heart Transplantation | 1 | 2023 | 736 | 0.510 |
Why?
| | Liver | 7 | 2022 | 1884 | 0.510 |
Why?
| | Transplant Recipients | 3 | 2025 | 180 | 0.500 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2024 | 1137 | 0.490 |
Why?
| | Wounds and Injuries | 5 | 2025 | 952 | 0.460 |
Why?
| | Health Services Accessibility | 4 | 2026 | 1091 | 0.460 |
Why?
| | Renal Nutcracker Syndrome | 2 | 2025 | 8 | 0.440 |
Why?
| | Parents | 2 | 2020 | 1401 | 0.430 |
Why?
| | Male | 48 | 2026 | 72035 | 0.420 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2024 | 265 | 0.410 |
Why?
| | Treatment Outcome | 20 | 2026 | 11643 | 0.400 |
Why?
| | Waiting Lists | 7 | 2026 | 263 | 0.380 |
Why?
| | Registries | 2 | 2025 | 2382 | 0.370 |
Why?
| | Female | 41 | 2026 | 77976 | 0.370 |
Why?
| | Acute Kidney Injury | 4 | 2021 | 862 | 0.360 |
Why?
| | Adult | 29 | 2026 | 40262 | 0.360 |
Why?
| | Creatinine | 4 | 2023 | 505 | 0.350 |
Why?
| | Pancreatic Neoplasms | 4 | 2024 | 918 | 0.350 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2014 | 1217 | 0.350 |
Why?
| | Social Determinants of Health | 2 | 2026 | 299 | 0.350 |
Why?
| | Saline Solution, Hypertonic | 3 | 2014 | 42 | 0.340 |
Why?
| | Obesity | 6 | 2025 | 3057 | 0.340 |
Why?
| | United States | 17 | 2026 | 15876 | 0.320 |
Why?
| | Multiple Organ Failure | 1 | 2011 | 124 | 0.320 |
Why?
| | NF-kappa B | 4 | 2014 | 661 | 0.310 |
Why?
| | Predictive Value of Tests | 7 | 2025 | 2111 | 0.310 |
Why?
| | Adenocarcinoma | 3 | 2024 | 927 | 0.300 |
Why?
| | Time Factors | 13 | 2026 | 7155 | 0.300 |
Why?
| | Ablation Techniques | 2 | 2020 | 36 | 0.290 |
Why?
| | Thrombocytopenia | 1 | 2011 | 205 | 0.290 |
Why?
| | Warm Ischemia | 2 | 2020 | 18 | 0.290 |
Why?
| | Renal Veins | 2 | 2025 | 18 | 0.280 |
Why?
| | Thrombosis | 3 | 2022 | 393 | 0.270 |
Why?
| | Aged | 19 | 2026 | 25850 | 0.260 |
Why?
| | Transplantation, Autologous | 2 | 2025 | 290 | 0.250 |
Why?
| | Risk Factors | 12 | 2025 | 10699 | 0.250 |
Why?
| | Survival Rate | 5 | 2024 | 2088 | 0.240 |
Why?
| | Markov Chains | 5 | 2025 | 126 | 0.240 |
Why?
| | Necrosis | 3 | 2021 | 244 | 0.240 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 2025 | 7 | 0.230 |
Why?
| | Fibrinolysin | 1 | 2025 | 19 | 0.230 |
Why?
| | Epithelial Cells | 3 | 2014 | 1125 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 382 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 377 | 0.220 |
Why?
| | Flank Pain | 1 | 2024 | 9 | 0.220 |
Why?
| | Metabolomics | 3 | 2019 | 726 | 0.220 |
Why?
| | Colonoscopy | 1 | 2007 | 260 | 0.210 |
Why?
| | Weight Loss | 4 | 2025 | 832 | 0.210 |
Why?
| | Prospective Studies | 4 | 2020 | 7970 | 0.210 |
Why?
| | Tumor Burden | 3 | 2020 | 319 | 0.210 |
Why?
| | Tissue and Organ Harvesting | 1 | 2024 | 73 | 0.200 |
Why?
| | Lung | 3 | 2014 | 4108 | 0.200 |
Why?
| | Salvage Therapy | 2 | 2024 | 162 | 0.200 |
Why?
| | Choledochostomy | 1 | 2022 | 10 | 0.190 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2022 | 26 | 0.190 |
Why?
| | Caspase 1 | 2 | 2021 | 148 | 0.190 |
Why?
| | Plasminogen Activator Inhibitor 1 | 2 | 2022 | 84 | 0.190 |
Why?
| | Risk Assessment | 7 | 2022 | 3637 | 0.190 |
Why?
| | Antiviral Agents | 2 | 2022 | 767 | 0.190 |
Why?
| | Bile Ducts | 1 | 2022 | 67 | 0.180 |
Why?
| | Lymph | 2 | 2016 | 31 | 0.180 |
Why?
| | Allografts | 1 | 2023 | 150 | 0.180 |
Why?
| | Preoperative Period | 2 | 2019 | 148 | 0.180 |
Why?
| | Hemostatics | 1 | 2022 | 61 | 0.170 |
Why?
| | Ventricular Remodeling | 1 | 2023 | 275 | 0.170 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2917 | 0.170 |
Why?
| | Nephrectomy | 2 | 2020 | 158 | 0.170 |
Why?
| | Stents | 1 | 2025 | 556 | 0.170 |
Why?
| | Surgeons | 1 | 2025 | 338 | 0.160 |
Why?
| | Intraoperative Period | 1 | 2020 | 69 | 0.160 |
Why?
| | Cell Line | 3 | 2018 | 2879 | 0.160 |
Why?
| | Computer Systems | 1 | 2020 | 56 | 0.160 |
Why?
| | Reperfusion Injury | 2 | 2021 | 300 | 0.160 |
Why?
| | Viscosity | 1 | 2020 | 90 | 0.160 |
Why?
| | Models, Animal | 2 | 2020 | 392 | 0.160 |
Why?
| | Liver Function Tests | 1 | 2020 | 106 | 0.160 |
Why?
| | Short Bowel Syndrome | 1 | 2020 | 27 | 0.160 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 70 | 0.160 |
Why?
| | Caspase 3 | 2 | 2018 | 238 | 0.160 |
Why?
| | Hepacivirus | 1 | 2022 | 243 | 0.160 |
Why?
| | Shock, Hemorrhagic | 2 | 2016 | 201 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1087 | 0.150 |
Why?
| | Pancreatectomy | 2 | 2024 | 285 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 316 | 0.150 |
Why?
| | Toll-Like Receptor 4 | 1 | 2021 | 276 | 0.150 |
Why?
| | Thromboembolism | 1 | 2020 | 125 | 0.150 |
Why?
| | Digestive System Surgical Procedures | 1 | 2020 | 109 | 0.150 |
Why?
| | Liver Diseases | 1 | 2022 | 304 | 0.140 |
Why?
| | Transplantation, Homologous | 1 | 2020 | 415 | 0.140 |
Why?
| | Follow-Up Studies | 4 | 2020 | 5389 | 0.140 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5988 | 0.140 |
Why?
| | Incidence | 2 | 2025 | 2870 | 0.130 |
Why?
| | Klebsiella pneumoniae | 1 | 2017 | 47 | 0.130 |
Why?
| | Case-Control Studies | 3 | 2023 | 3592 | 0.130 |
Why?
| | Platelet Count | 2 | 2022 | 96 | 0.130 |
Why?
| | Plasma | 2 | 2016 | 224 | 0.130 |
Why?
| | Critical Care | 1 | 2023 | 694 | 0.130 |
Why?
| | Drug Overdose | 1 | 2021 | 367 | 0.130 |
Why?
| | Goals | 1 | 2018 | 180 | 0.120 |
Why?
| | Young Adult | 7 | 2024 | 13990 | 0.120 |
Why?
| | Arteriovenous Anastomosis | 1 | 2015 | 13 | 0.120 |
Why?
| | Hepatectomy | 1 | 2018 | 273 | 0.110 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 43 | 0.110 |
Why?
| | Airway Extubation | 1 | 2016 | 60 | 0.110 |
Why?
| | Renal Artery | 1 | 2015 | 43 | 0.110 |
Why?
| | Aorta, Abdominal | 1 | 2015 | 52 | 0.110 |
Why?
| | Isoantibodies | 1 | 2015 | 57 | 0.110 |
Why?
| | Vascular Surgical Procedures | 2 | 2015 | 339 | 0.110 |
Why?
| | ABO Blood-Group System | 1 | 2015 | 57 | 0.110 |
Why?
| | Microsurgery | 1 | 2015 | 72 | 0.110 |
Why?
| | Rewarming | 1 | 2014 | 21 | 0.110 |
Why?
| | Early Detection of Cancer | 1 | 2019 | 462 | 0.100 |
Why?
| | Phosphorylation | 4 | 2014 | 1732 | 0.100 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 182 | 0.100 |
Why?
| | Kidney Tubules | 1 | 2014 | 117 | 0.100 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 146 | 0.100 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2018 | 365 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 576 | 0.100 |
Why?
| | Cholestasis | 1 | 2016 | 219 | 0.100 |
Why?
| | Age Factors | 4 | 2021 | 3313 | 0.100 |
Why?
| | Osmolar Concentration | 1 | 2013 | 167 | 0.100 |
Why?
| | Erythrocyte Transfusion | 2 | 2016 | 230 | 0.100 |
Why?
| | ROC Curve | 2 | 2025 | 612 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 248 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2014 | 395 | 0.090 |
Why?
| | Biomarkers | 3 | 2019 | 4254 | 0.090 |
Why?
| | Metabolome | 1 | 2016 | 384 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1313 | 0.090 |
Why?
| | Autophagy | 1 | 2014 | 285 | 0.090 |
Why?
| | Recovery of Function | 1 | 2016 | 706 | 0.090 |
Why?
| | Sirolimus | 1 | 2013 | 281 | 0.090 |
Why?
| | Microvessels | 1 | 2013 | 98 | 0.090 |
Why?
| | Patient Selection | 1 | 2015 | 719 | 0.090 |
Why?
| | Liver Cirrhosis | 1 | 2013 | 288 | 0.090 |
Why?
| | Models, Biological | 1 | 2019 | 1820 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4556 | 0.080 |
Why?
| | Animals | 9 | 2021 | 38030 | 0.080 |
Why?
| | Length of Stay | 2 | 2026 | 1335 | 0.080 |
Why?
| | Shock | 2 | 2024 | 108 | 0.070 |
Why?
| | Neoplasms | 1 | 2025 | 2870 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 846 | 0.070 |
Why?
| | Postoperative Period | 2 | 2020 | 353 | 0.070 |
Why?
| | Injury Severity Score | 1 | 2011 | 600 | 0.070 |
Why?
| | Hypoxia | 1 | 2016 | 1199 | 0.070 |
Why?
| | Kidney Function Tests | 2 | 2020 | 157 | 0.070 |
Why?
| | Odds Ratio | 1 | 2011 | 1072 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1495 | 0.070 |
Why?
| | Renal Dialysis | 2 | 2023 | 462 | 0.070 |
Why?
| | Mice | 6 | 2021 | 18329 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 416 | 0.070 |
Why?
| | Colonoscopes | 1 | 2007 | 5 | 0.070 |
Why?
| | Protein Transport | 1 | 2009 | 441 | 0.070 |
Why?
| | Barium Sulfate | 1 | 2007 | 13 | 0.070 |
Why?
| | I-kappa B Kinase | 1 | 2007 | 51 | 0.070 |
Why?
| | Mesentery | 1 | 2007 | 45 | 0.070 |
Why?
| | Cecum | 1 | 2007 | 37 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2020 | 462 | 0.060 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.060 |
Why?
| | Betacoronavirus | 2 | 2020 | 285 | 0.060 |
Why?
| | Enema | 1 | 2007 | 46 | 0.060 |
Why?
| | Body Mass Index | 2 | 2026 | 2420 | 0.060 |
Why?
| | Cause of Death | 2 | 2021 | 464 | 0.060 |
Why?
| | Blotting, Western | 1 | 2009 | 1187 | 0.060 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2007 | 40 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2007 | 72 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 573 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2009 | 508 | 0.060 |
Why?
| | Cell Survival | 1 | 2009 | 1098 | 0.060 |
Why?
| | Recurrence | 2 | 2023 | 1134 | 0.060 |
Why?
| | Logistic Models | 1 | 2011 | 2104 | 0.060 |
Why?
| | Quality of Life | 1 | 2018 | 3166 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1382 | 0.060 |
Why?
| | Operative Time | 1 | 2026 | 175 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2009 | 1172 | 0.060 |
Why?
| | Child | 6 | 2022 | 22537 | 0.060 |
Why?
| | Mass Spectrometry | 2 | 2019 | 744 | 0.050 |
Why?
| | Adolescent | 5 | 2024 | 22281 | 0.050 |
Why?
| | Ampulla of Vater | 1 | 2024 | 39 | 0.050 |
Why?
| | Trauma Centers | 1 | 2006 | 462 | 0.050 |
Why?
| | Databases, Factual | 2 | 2021 | 1484 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2024 | 218 | 0.050 |
Why?
| | Inflammation | 1 | 2014 | 2877 | 0.050 |
Why?
| | Erythrocytes | 1 | 2009 | 757 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2020 | 8243 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1322 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 71 | 0.050 |
Why?
| | Pain Measurement | 1 | 2024 | 552 | 0.040 |
Why?
| | Platelet Transfusion | 1 | 2022 | 80 | 0.040 |
Why?
| | Patients | 1 | 2023 | 178 | 0.040 |
Why?
| | Propensity Score | 1 | 2023 | 367 | 0.040 |
Why?
| | Hemostasis | 1 | 2022 | 102 | 0.040 |
Why?
| | Pandemics | 2 | 2020 | 1682 | 0.040 |
Why?
| | Cytokines | 1 | 2009 | 2061 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2020 | 1461 | 0.040 |
Why?
| | Child Abuse | 1 | 2006 | 550 | 0.040 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 10 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2020 | 81 | 0.040 |
Why?
| | Partial Thromboplastin Time | 1 | 2020 | 50 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 222 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2730 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 93 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2019 | 18 | 0.040 |
Why?
| | Databases as Topic | 1 | 1999 | 71 | 0.040 |
Why?
| | alpha-Fetoproteins | 1 | 2019 | 40 | 0.040 |
Why?
| | Colorectal Neoplasms | 1 | 2007 | 844 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6424 | 0.040 |
Why?
| | Blood Platelets | 1 | 2022 | 399 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2020 | 768 | 0.040 |
Why?
| | Long-Term Care | 1 | 1999 | 117 | 0.030 |
Why?
| | Ischemia | 1 | 2020 | 421 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2018 | 333 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 358 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2016 | 36 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2016 | 76 | 0.030 |
Why?
| | Sepsis | 1 | 2022 | 640 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1131 | 0.030 |
Why?
| | Mutation | 1 | 2007 | 4085 | 0.030 |
Why?
| | Cohort Studies | 1 | 2026 | 5935 | 0.030 |
Why?
| | Preoperative Care | 1 | 2018 | 379 | 0.030 |
Why?
| | Renal Artery Obstruction | 1 | 2015 | 29 | 0.030 |
Why?
| | Transplants | 1 | 2015 | 39 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2015 | 143 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 643 | 0.030 |
Why?
| | Renal Circulation | 1 | 2015 | 75 | 0.030 |
Why?
| | Signal Transduction | 2 | 2021 | 5221 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2015 | 157 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 519 | 0.030 |
Why?
| | United States Department of Veterans Affairs | 1 | 1999 | 765 | 0.030 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 85 | 0.030 |
Why?
| | Macrolides | 1 | 2014 | 69 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 189 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1264 | 0.030 |
Why?
| | Endothelial Cells | 2 | 2013 | 869 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3119 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2016 | 593 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 916 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2014 | 4146 | 0.030 |
Why?
| | Hemoglobins | 1 | 2016 | 383 | 0.020 |
Why?
| | Critical Illness | 1 | 2020 | 889 | 0.020 |
Why?
| | Motivation | 1 | 2018 | 605 | 0.020 |
Why?
| | Hepatocytes | 1 | 2014 | 221 | 0.020 |
Why?
| | Reoperation | 1 | 2016 | 629 | 0.020 |
Why?
| | Leukocytes | 1 | 2014 | 295 | 0.020 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2013 | 138 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2840 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 266 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2013 | 271 | 0.020 |
Why?
| | Swine | 1 | 2014 | 831 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1533 | 0.020 |
Why?
| | Infant | 2 | 2021 | 10022 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2013 | 454 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 324 | 0.020 |
Why?
| | Child, Preschool | 2 | 2021 | 11774 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4278 | 0.020 |
Why?
| | Hemodynamics | 1 | 2015 | 1119 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2013 | 302 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2009 | 39 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2009 | 132 | 0.020 |
Why?
| | Paracrine Communication | 1 | 2009 | 67 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1559 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3403 | 0.020 |
Why?
| | Neutrophils | 1 | 2013 | 1134 | 0.020 |
Why?
| | Veterans | 1 | 1999 | 1600 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 112 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 851 | 0.010 |
Why?
| | Intestine, Small | 1 | 2007 | 166 | 0.010 |
Why?
| | Exons | 1 | 2007 | 358 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 863 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2009 | 1126 | 0.010 |
Why?
| | Blood Preservation | 1 | 2009 | 354 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2007 | 618 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 477 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2007 | 2525 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1046 | 0.010 |
Why?
| | Manuals as Topic | 1 | 1999 | 16 | 0.010 |
Why?
| | Rats | 1 | 2007 | 5592 | 0.010 |
Why?
| | Demography | 1 | 1999 | 284 | 0.010 |
Why?
| | Health Resources | 1 | 1999 | 129 | 0.010 |
Why?
| | Nursing Homes | 1 | 1999 | 172 | 0.010 |
Why?
| | Health Services Needs and Demand | 1 | 1999 | 279 | 0.010 |
Why?
| | Patient Admission | 1 | 1999 | 218 | 0.010 |
Why?
| | Women's Health | 1 | 1999 | 308 | 0.010 |
Why?
| | Data Collection | 1 | 1999 | 633 | 0.010 |
Why?
| | Colorado | 1 | 2006 | 4562 | 0.010 |
Why?
| | Ambulatory Care | 1 | 1999 | 597 | 0.010 |
Why?
| | Internet | 1 | 1999 | 698 | 0.010 |
Why?
| | Sex Factors | 1 | 1999 | 2096 | 0.010 |
Why?
| | Hospitalization | 1 | 1999 | 2424 | 0.000 |
Why?
|
|
Nydam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|